# Rui‐Hua Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rui-hua-xu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,649 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 104 |
| i10-index | 569 |
| Last Known Institution | Sun Yat-sen University |
| OpenAlex ID | https://openalex.org/A5101613292 |
| ORCID iD | https://orcid.org/0000-0001-9771-8534 |
| Works | 1,458 |

## Researcher papers

- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)](https://scholariq.org/papers/efficacy-safety-and-correlative-biomarkers-of-toripalimab-in-previously-treated/)
- [Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma](https://scholariq.org/papers/toripalimab-plus-chemotherapy-for-recurrent-or-metastatic-nasopharyngeal/)
- [Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial](https://scholariq.org/papers/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [Sun Yat-sen University](https://scholariq.org/institutions/sun-yat-sen-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.